Ramucirumab: a novel antiangiogenic agent

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

(2017) D. R. Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.

(2017) Rocio Garcia-Carbonero et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

(2012) H. Wong et al.   ONCOLOGIST

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies

(2011) Matthew C. Franklin et al.   STRUCTURE

Ramucirumab (IMC-1121B): a novel attack on angiogenesis

(2010) Jennifer L Spratlin et al.   Future Oncology

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

TRIO-012: A Multicenter, Multinational, Randomized, Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally Recurrent or Metastatic Breast Cancer

(2009) John Mackey et al.   Clinical Breast Cancer

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY